Pennington Kelly M, Simonetto Douglas, Taner Timucin, Mangaonkar Abhishek A
Division of Pulmonary Medicine, Mayo Clinic, Rochester, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA.
Curr Hematol Malig Rep. 2024 Dec;19(6):293-299. doi: 10.1007/s11899-024-00724-z. Epub 2024 Feb 5.
This study aimed to summarize evidence and provide consensus-based guidelines for management of transplantation in patients with telomere biology disorders (TBD). Specifically, this review focuses on clinical management of lung, liver, and bone marrow transplantation in TBD patients.
TBD patients have specific unique biological vulnerabilities such as T cell immunodeficiency, susceptibility to infections, hypersensitivity to chemotherapy and radiation, and cytopenias. Furthermore, multiple organ involvement at diagnosis makes clinical management especially challenging due to higher degree of organ damage, and stress-induced telomeric crisis. Sequential and combined organ transplants, development of novel radiation and alkylator-free conditioning regimen, and use of novel drugs for graft-versus-host disease prophylaxis are some of the recent updates in the field. Multidisciplinary management is essential to optimize transplant outcomes in patients with TBD. In this review, we provide consensus-based transplant management guidelines for clinical management of transplant in TBD.
本研究旨在总结证据,并为端粒生物学障碍(TBD)患者的移植管理提供基于共识的指南。具体而言,本综述聚焦于TBD患者肺、肝和骨髓移植的临床管理。
TBD患者具有特定的独特生物学易损性,如T细胞免疫缺陷、易感染、对化疗和放疗过敏以及血细胞减少。此外,诊断时多器官受累因器官损伤程度较高和应激诱导的端粒危机而使临床管理尤其具有挑战性。序贯和联合器官移植、新型无辐射和无烷化剂预处理方案的开发以及使用新型药物预防移植物抗宿主病是该领域最近的一些进展。多学科管理对于优化TBD患者的移植结局至关重要。在本综述中,我们为TBD患者移植的临床管理提供基于共识的移植管理指南。